Evidence map›Paper›PMID 39059467›Full record

ArticleBiological psychiatry. Cognitive neuroscience and neuroimaging2024

Neural Correlates of Metacognition Impairment in Opioid Addiction.

Scott J Moeller, Sameera Abeykoon, Pari Dhayagude, Benjamin Varnas, Jodi J Weinstein, Greg Perlman, Roberto Gil, Stephen M Fleming, Anissa Abi-Dargham

Abstract read
In one paragraph

Article in Biological psychiatry. Cognitive neuroscience and neuroimaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Towards an integrative neuroscience of metacognition.Nature reviews. Neuroscience · 2026
    Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Scott J MoellerDepartment of Psychiatry and Behavioral Health, Renaissance School of Medicine at Stony Brook University, Stony Brook, New York. Electronic address: scott.moeller@stonybrookmedicine.edu.
Sameera AbeykoonDepartment of Psychiatry and Behavioral Health, Renaissance School of Medicine at Stony Brook University, Stony Brook, New York.
Pari DhayagudeUniversity of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Benjamin VarnasDepartment of Psychiatry and Behavioral Health, Renaissance School of Medicine at Stony Brook University, Stony Brook, New York.
Jodi J WeinsteinDepartment of Psychiatry and Behavioral Health, Renaissance School of Medicine at Stony Brook University, Stony Brook, New York.
Greg PerlmanDepartment of Psychiatry and Behavioral Health, Renaissance School of Medicine at Stony Brook University, Stony Brook, New York.
Roberto GilDepartment of Psychiatry and Behavioral Health, Renaissance School of Medicine at Stony Brook University, Stony Brook, New York.
Stephen M FlemingMax Planck UCL Centre for Computational Psychiatry and Ageing Research, University College London, London, United Kingdom; Wellcome Centre for Human Neuroimaging, University College London, London, United Kingdom; Department of Experimental Psychology, University College London, London, United Kingdom.
Anissa Abi-DarghamDepartment of Psychiatry and Behavioral Health, Renaissance School of Medicine at Stony Brook University, Stony Brook, New York.

Funding

Neurocircuitry of clinical insight predicting relapse outcomes in opioid addictionR01DA051420 · NIDA · STATE UNIVERSITY NEW YORK STONY BROOK · PI MOELLER, SCOTT J · 2020 to 2025
$2.9M
Neuromelanin MRI: A tool for non-invasive investigation of dopaminergic abnormalities in adolescent substance use.R01DA057268 · NIDA · STATE UNIVERSITY NEW YORK STONY BROOK · PI Greg Perlman · 2023 to 2026
$2.9M
Neural, endocrine, and behavioral markers of psychosocial stress predicting drug use outcomes in human opioid addictionR01DA049733 · NIDA · STATE UNIVERSITY NEW YORK STONY BROOK · PI MOELLER, SCOTT J · 2021 to 2025
$2.6M
Towards an Integrated Understanding of Neurotransmitter Dysfunction in Schizophrenia: a Multimodal MRI StudyK23MH115291 · NIMH · STATE UNIVERSITY NEW YORK STONY BROOK · PI WEINSTEIN, JODI JAY · 2018 to 2024
$1.2M
Functional MRI in SchizophreniaR21MH126260 · NIMH · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI DAI, WEIYING, HE, XIANG · 2022 to 2023
$467k
Neural and neurochemical correlates of metacognition impairment in opioid addictionR21DA048196 · NIDA · STATE UNIVERSITY NEW YORK STONY BROOK · PI MOELLER, SCOTT J · 2020 to 2021
$439k
Cholinergic transmission abnormalities associated with smoking behavior in humansR21DA051179 · NIDA · STATE UNIVERSITY NEW YORK STONY BROOK · PI MOELLER, SCOTT J · 2020 to 2021
$439k
NIDA NIH HHS R01 DA049733NIDA NIH HHS R01 DA051420NIDA NIH HHS R01 DA057268NIDA NIH HHS R21 DA048196NIDA NIH HHS R21 DA051179NIMH NIH HHS K23 MH115291NIMH NIH HHS R21 MH126260
6 · The paper itself

Abstract

backgroundIndividuals with substance use disorder show impaired self-awareness of ongoing behavior. This deficit suggests problems with metacognition, which has been operationalized in the cognitive neuroscience literature as the ability to monitor and evaluate the success of one's own cognition and behavior. However, the neural mechanisms of metacognition have not been characterized in a population with drug addiction.

methodsCommunity samples of participants with opioid use disorder (OUD) (n = 27) and healthy control participants (n = 29) performed a previously validated functional magnetic resonance imaging metacognition task (perceptual decision-making task along with confidence ratings of performance). Measures of recent drug use and addiction severity were also acquired.

resultsIndividuals with OUD had lower metacognitive sensitivity (i.e., disconnection between task performance and task-related confidence) than control individuals. Trial-by-trial analyses showed that this overall group difference was driven by (suboptimally) low confidence in participants with OUD during correct trials. In functional magnetic resonance imaging analyses, the task engaged an expected network of brain regions (e.g., rostrolateral prefrontal cortex and dorsal anterior cingulate/supplementary motor area, both previously linked to metacognition); group differences emerged in a large ventral anterior cluster that included the medial and lateral orbitofrontal cortex and striatum (higher activation in OUD). Trial-by-trial functional magnetic resonance imaging analyses showed group differences in rostrolateral prefrontal cortex activation, which further correlated with metacognitive behavior across all participants. Exploratory analyses suggested that the behavioral and neural group differences were exacerbated by recent illicit opioid use and unexplained by general cognition.

conclusionsWith confirmation and extension of these findings, metacognition and its associated neural circuits could become new, promising therapeutic targets in addiction.

Indexed as

Magnetic Resonance ImagingMetacognitionOpioid-Related DisordersAdultBrainDecision MakingFemaleHumansMaleMiddle AgedYoung AdultAddictionClinical neuroscienceCognitive neurosciencefMRIMetacognitionOpioid use disorder

Identifiers

PMID39059467
PMCPMC11540741

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.